

1 **Figure S1: Peptide tables**

2 Tables describing peptide pools derived from S, N, and M proteins from USA-WA1/2020 strain
3 of SARS-CoV-2. S2 and S3 peptide pools from Spike protein contain the first and second halves
4 of the Spike receptor-binding domain (RBD), respectively.

5 **Figure S2: Anti-Spike IgG titers are not correlated with the magnitude of the Ag-specific T**
6 **cell response to Spike RBD.**

7 A.) Plasma endpoint titers for Spike RBD IgG do not correlate with magnitude of T cell
8 responses for S2 and S3 pools comprising Spike RBD in CN samples. B.) Plasma endpoint titers
9 for Spike RBD IgG do not correlate with T cell responses to S2 and S3 pools in CC samples.
10 Data combined from 20 experiments with all ELISPOT conditions plated in duplicate and
11 ELISA in triplicate and plotted as mean \pm SEM

12 **Figure S3: Gating strategies and fluorescence-minus-one (FMOs) for cytokine production.**

13 A.) Gating strategy for memory T cells by CD45RA/RO, CCR7, and CD27 expression. B.)
14 FMOs used for gating in determining cytokine positive T cells. C.) Gating strategy for CD4⁺ Tfh
15 cells.

16 **Figure S4: Similar total percentages of CD4⁺ and CD8⁺ T cell subsets between groups.**

17 CN, CC, and HC groups displayed no significant differences in percentages of CD8 TCM or
18 TEM cells. While there was a significant increase in CD4 TEM cells as a percentage of total
19 CD4 T cells in CN vs. other groups, no other cell subset including CD4 TCM, TEMRA, or Tfh
20 cells were significantly different between groups.

21 **Figure S5: Correlations between N-specific IgG titers and days post-infection; cytokine and**
22 **granzyme production in unstimulated CD4⁺ T cells between groups.**

23 A.) Regression analysis of N-specific IgG titers compared to time the sample was obtained post-
24 symptom onset. No significant correlations were found. B.) Magnitude of various TH1-type
25 cytokines and cytotoxic granules produced as a percentage of total CD4⁺ T cells in the
26 unstimulated condition between CN, CC, and HC groups. C.) IL-21 production in unstimulated
27 CD4⁺ T cells is significantly elevated in CN over CC and HC subjects. Data representative of 10
28 experiments with a total of n=35 CN, 11 CC, and 9 HC. *p<0.05, **p<0.01 by two-tailed
29 Student's t test with Welch's correction.

30 **Figure S6: SPICE analysis on unstimulated T cell subsets.**

31 A.) No differences in unstimulated CD4⁺ T cell polyfunctionality exist between CN, CC, and HC
32 subjects (associated with Fig. 3F). B) Unstimulated CD8⁺ TEM from CC subjects produce
33 slightly more perforin than CN patients (associated with Fig. 4F). C.) Unstimulated CD8⁺
34 TEMRA cells have no differences in polyfunctionality between CN and CC subjects (associated
35 with Fig. 4G).

36 **Figure S7: NIH toolbox and PROMIS-57 scores from CN patients correlate strongly with**
37 **Ag-specific memory T cell responses to SARS-CoV-2.**

38 A.) Separation of CN patients into quartiles based on T scores for individual parameters from
39 NIH Toolbox or PROMIS-57 patient-reported surveys. Only quartiles 1 and 4 (red boxes) were
40 used as comparison groups for SPICE analyses in B-K and Fig. 5. B.) CN patients reporting high
41 depression scores have significantly enhanced production of granzymes A/B/M and perforin
42 from CD8⁺ TCM compared with those with low T scores after Spike peptide stimulation C.)

43 CD8⁺ TCM from CN patients with high depression scores produce 15-fold more category 1
44 cytokines than those in Q1. D.) CN patients with high cognitive scores for working memory had
45 enhancement of N protein-specific polyfunctional CD8 TEMRA cells producing granzyme A/B.
46 E.) Heatmap showing that CN patients scoring high on working memory on had CD8⁺ TEMRA
47 cells producing 15-fold more granzymes A/B after N pool stimulation than low scorers. F.) CN
48 patients scoring low on processing speed tests had more polyfunctional CD4⁺ TEMRA responses
49 to Spike peptides than those scoring high. G.) Heatmap showing that CD4⁺ TEMRA from CN in
50 Q1 have a ~6-fold elevation in production of category 1 cytokines and a ~2-fold increase in
51 category 3 cytokine production over Q4. H.) CD4⁺ TEMRA cells produce more granzymes A/B
52 after M pool stimulation in CN patients who scored higher on working memory tests. I.)
53 Heatmap showing that CN in Q1 for Working Memory have ~10-fold elevation in category 1
54 cytokine production compared with those in Q4, while those in Q4 have ~6-fold enhancement in
55 category 4 cytokines. J.) CN subjects reporting high levels of pain have polyfunctional CD4⁺
56 TCM significantly polarized towards granzyme A/B/M production after Spike peptide
57 stimulation. K.) Spike-specific CD4⁺ TCM from CN in Q4 for Global Pain scores produce ~20-
58 fold more granzyme A/B/M compared with low scorers.

59 **Figure S8: Vaccine study recruitment table**

60 Table showing the number of samples used per group per time point for Fig. 6. Participants were
61 enrolled on a rolling basis and the variation in sample size for each time point reflects the timing
62 of enrollment.

63

64 **Figure S9: Kinetics of Spike pool-specific T cell responses over 4 months in vaccinated CC**
65 **and HC but not CN subjects.**

66 IFN- γ production from T cells in response to 6 different pools of Spike protein peptide wane
67 over time in CC and HC groups, while remaining high in CN up to V4 post-vaccination. Data
68 combined from 10 individual experiments with all ELISPOT conditions plated in duplicate.

69 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.0001$ by two-way ANOVA with Tukey's posttest or by two-tailed
70 Student's t test.

Spike pools	Amino acids	Protein region
S1 (30 peptides)	1-220	
S2 (30 peptides)	211-430	Contains 1 st half of RBD
S3 (30 peptides)	421-640	Contains 2 nd half of RBD
S4 (30 peptides)	631-850	
S5 (30 peptides)	841-1130	
S6 (31 peptides)	1121-1273	

Nucleocapsid pools	Amino acids
N1 (20 peptides)	1-150
N2 (20 peptides)	141-290
N3 (19 peptides)	281-419

Membrane pools	Amino acids
M1 (10 peptides)	1-80
M2 (10 peptides)	71-150
M3 (11 peptides)	141-222

Figure S1






Figure S2

A. Memory T cell gating, CD8+ T cells:



B. FMO for cytokine gating, CD3+ T cells:



C. TFh cell gating:




Figure S3





Figure S4



p=0.55
R²=0.021





Figure S5






Figure S6




Figure S7

Study visit	CN+	CC	HC
V0	n=16	n=12	n=19
V1	n=8	n=11	n=20
V2	n=11	n=9	n=20
V3	n=8	n=8	n=14
V4	n=6	n=8	n=9

Figure S8




Figure S9